CP-775146
Based on 1 Customer Validation
CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.70%
- CAS No.: 702680-17-9
- 화학식: C26H33NO4
- 분자량:423.54
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
제품 설명
In Vitro
CP-775146 induces PPARα transcriptional activity in a reporter assay, the EC50s of 57 nM and 284 nM for human and rat receptors, respectively, expressed in HepG2 cells[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (4-week-old) with a high-fat diet (HFD)[2]
-
Dosage:0.1 mg/kg, 0.3 mg/kg
-
Administration:Intraperitoneal injection (i.p.); daily; for 3 days
-
Result:Reduced the serum levels of liver enzymes, such as ALT and AST and lipid metabolism-related biomarkers, including TGs and LDL-c, non-HDL-c, and hepatic TG content, at a dosage of 0.1 mg/kg.
HFD-induced pathological liver changes improved.
The expression of genes involved in liver fatty acid oxidation (Acadl, Acox-1, CPT-1, and Ehhadh) was upregulated.
Induced the expression of thermogenesis genes (Cidea, Ucp1) and lipolysis genes (Hsl, Atgl).
Chemical Information
-
CAS No. 702680-17-9
-
Appearance Solid
-
분자량 423.54
-
화학식 C26H33NO4
-
Color White to off-white
-
SMILES
CC(OC1=CC=CC([C@H]2CN(C(CC3=CC=C(C(C)C)C=C3)=O)CCC2)=C1)(C)C(O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
DMSO : 42 mg/mL (99.16 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
순도&문서
-
Data Sheet (271 KB)
-
SDS (458 KB)
- English - EN (458 KB)
- Français - FR (458 KB)
- Deutsch - DE (458 KB)
- Norwegian - NO (458 KB)
- Español - ES (458 KB)
- Swedish - SV (458 KB)
- Italian - IT (458 KB)
- Korean - KR (458 KB)
- Portuguese - PT (458 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kane CD, et al. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306. [Content Brief]
[2]. Shengjie Tang, et al. The Effects of New Selective PPAR α Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism. J Diabetes Res. 2020 May 4;2020:4179852. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3611 mL | 11.8053 mL | 23.6105 mL | 59.0263 mL |
| 5 mM | 0.4722 mL | 2.3611 mL | 4.7221 mL | 11.8053 mL | |
| 10 mM | 0.2361 mL | 1.1805 mL | 2.3611 mL | 5.9026 mL | |
| 15 mM | 0.1574 mL | 0.7870 mL | 1.5740 mL | 3.9351 mL | |
| 20 mM | 0.1181 mL | 0.5903 mL | 1.1805 mL | 2.9513 mL | |
| 25 mM | 0.0944 mL | 0.4722 mL | 0.9444 mL | 2.3611 mL | |
| 30 mM | 0.0787 mL | 0.3935 mL | 0.7870 mL | 1.9675 mL | |
| 40 mM | 0.0590 mL | 0.2951 mL | 0.5903 mL | 1.4757 mL | |
| 50 mM | 0.0472 mL | 0.2361 mL | 0.4722 mL | 1.1805 mL | |
| 60 mM | 0.0394 mL | 0.1968 mL | 0.3935 mL | 0.9838 mL | |
| 80 mM | 0.0295 mL | 0.1476 mL | 0.2951 mL | 0.7378 mL |